Table 3 Comparison of clinically actionable variants identified in FH not available and available cohorts
From: Family history assessment significantly enhances delivery of precision medicine in the genomics era
|  |  | Increased FH risk n = 73 | Average FH risk n = 793 | RR (95% CI) | p value | Increased FH risk n = 73 | FH not available n = 884 | RR (95% CI) | p value |
|---|---|---|---|---|---|---|---|---|---|
Cancer gene panel | |||||||||
 No of clinically actionable variants (%) | 10 (13.7) | 17 (2.1) | 6.39 (3.0–13.4) | 0.0001 | 10 (13.7) | 17 (1.9) | 7.1 (3.3–14.9) | 0.0001 | |
ACMG SF v2.0 cancer genes | |||||||||
 No of clinically actionable variants (%) | 5 (6.8) | 3 (0.4) | 18.1 (4.4–74.2) | 0.0002 | 5 (6.8) | 4 (0.5) | 15.13 (4.1–55.1) | 0.0001 | |